CXCL8 and melanoma: Anti-IL-8 monoclonal antibody HuMax-IL8 (BMS-986253) was evaluated in phase Ib clinical study (NCT02536469) and showed good safety and tolerability, while the ongoing studies are presently evaluating the combination of IL-8 blockade and IC inhibitors in melanoma [178].